braz j infect dis. 2014;18(5):491–495
http://dx.doi.org/10.1016/j.bjid.2014.02.004
1413-8670/© 2014 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
Supplement Article
J Acquir Immune Defic Syndr Volume 78, Supplement 1, August 15, 2018 www.jaids.com
Case Study on Improving HIV Testing and Services for Children Orphaned or made Vulnerable by HIV (OVC)
Pakistan Global Antibiotic Resistance Partnership (GARP) was formed in the wake of international and national efforts for AMR curtailment. A group of experts from microbiology, infectious diseases and veterinary medicine formed a core group at the organizational meet...ing of GARP in Kathmandu, Nepal in July 2016. In the meeting, this core group was expanded to include other members from different sectors with the selection of the Chair and co-chairs. These were asked to serve on a voluntary basis, in their own individual capacities, with no personal gains, or gains to the institutions to which they are affiliated. The first phase of GARP took place from 2009 to 2011 and involved four countries: India, Kenya, South Africa and Vietnam. Phase one culminated in the 1st Global Forum on Bacterial Infections, held in October 2011 in New Delhi, India. In 2012, phase two of GARP was initiated with the addition of working groups in Mozambique, Tanzania, Nepal and Uganda. Phase three has added Bangladesh, Lao PDR, Nigeria, Pakistan and Zimbabwe to the network to date.
more
COVID-19 is a disease caused by a new strain of coronavirus, a new coronavirus associated with the severe acute respiratory syndrome (SARS) viruses family and some coronaviruses associated with common cold.
There is still no evidence that persons living with HIV have a higher risk of contracting CO...VID-19 or if they will experience further complications of the disease, in case of contracting it. Nevertheless, it is very important that persons with HIV take all necessary precautions to prevent the spread.
more
Tuberculosis cases, TB deaths
This inter-agency guidance document aims to supplement the COVAX demand creation package for COVID-19 vaccines with key considerations for humanitarian contexts and marginalized populations with specific access and communication needs.
21 Sept.2021
PHARMA’S RESPONSE TO THE COVID-19 VACCINES CRISIS. Update Feb., 14, 2022. In September 2021, Amnesty International published A Double Dose of Inequality, which assessed the extent to which the pharmaceutical industry was restricting access to Covid-19 vaccines. This report updates that assessment ...of five leading vaccine manufacturers, AstraZeneca plc, BioNTech SE, Johnson & Johnson, Moderna Inc., and Pfizer Inc. It also includes for the first time an assessment of the two largest Chinese vaccine producers, China National Pharmaceutical Group Co., Ltd. (Sinopharm) and Sinovac Biotech Ltd. (Sinovac).
more
The COVID-19 pandemic has impacted regular cardiovascular healthcare access and delivery. Service utilisation has declined, and excess cardiovascular mortality has been reported in several countries. We aim to estimate excess cardiovascular deaths in Chile during 2020.
ISN Public Affairs Kidney International Supplements (2020) 10, e19–e23